Sunitinib rechallenge in advanced renal cell carcinoma: outcomes of a multicenter retrospective study
Renal cell carcinoma
Sequential therapy
Issue Date: 
Editorial note: 
© Springer-Verlag GmbH Germany, part of Springer Nature 2019
Sánchez-Lorenzo, M. L. (María Luisa); Muñarriz, J. (Javier); Reynés, G. (Gaspar); et al. "Sunitinib rechallenge in advanced renal cell carcinoma: outcomes of a multicenter retrospective study". Cancer Chemotherapy and Pharmacology. 84, 2019, 781 - 789
Purpose: The aim of this multicenter study was to evaluate the clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) who received sunitinib retreatment. Methods: Clinical data from patients treated with sunitinib rechallenge in nine Spanish centers were retrospectively analyzed. All patients received first-line sunitinib until progression or intolerance, followed by one or more successive drugs and rechallenge with sunitinib thereafter. Results: Thirty-seven patients were included. At first-line treatment, objective response rate (ORR) was 69.4% and median progression-free survival (PFS) was 19.4 months. At rechallenge, ORR was 27.2% and 39.4% of patients obtained stabilization of disease. Median PFS was 6.2 months. Clinical benefit was obtained by 21 patients (75%) with > 6-month interval between sunitinib treatments and by 1 patient (20%) among those with ≤ 6-month interval (P = 0.016). Hemoglobin levels ≥ lower level of normal were associated with clinical benefit (P = 0.019) and with PFS (P = 0.004). Median overall survival from start of first-line sunitinib was 52.7 months. No new adverse events were observed at rechallenge. Conclusions: Sunitinib rechallenge is a feasible treatment option for selected patients with mRCC.

Files in This Item:
reserva 1.pdf
804.18 kB
Adobe PDF

Statistics and impact
0 citas en
0 citas en

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.